Gary Collins1, Douglas Altman. 1. Centre for Statistics in Medicine, University of Oxford, Oxford. gary.collins@csm.ox.ac.uk
Abstract
BACKGROUND: Chronic kidney disease is a major health concern that, if left untreated, may progress to end-stage kidney failure (ESKF). Identifying individuals at an increased risk of kidney disease and who might benefit from a therapeutic or preventive intervention is an important challenge. AIM: To evaluate the performance of the QKidney® scores for predicting 5-year risk of developing moderate-severe kidney disease and ESKF in an independent UK cohort of patients from general practice records. DESIGN AND SETTING: Prospective cohort study to evaluate the performance of two risk scores for kidney disease in 364 practices from the UK, contributing to The Health Improvement Network (THIN) database. METHOD: Data were obtained from 1.6 million patients registered with a general practice surgery between 1 January 2002 and 1 July 2008, aged 35-74 years, with 43,186 incident cases of moderate-severe kidney disease and 2663 incident cases of ESKF. This is the first recorded evidence of moderate-severe chronic kidney and ESKF as recorded in general practice records. RESULTS: The results from this independent and external validation of QKidney scores indicate that both scores showed good performance data for both moderate-severe kidney disease and ESKF, on a large cohort of general practice patients. Discrimination and calibration statistics were better for models including serum creatinine; however, there were considerable amounts of missing data for serum creatinine. QKidney scores both with and without serum creatinine were well calibrated. CONCLUSION: QKidney scores have been shown to be useful tools to predict the 5-year risk of moderate-severe kidney disease and ESKF in the UK.
BACKGROUND:Chronic kidney disease is a major health concern that, if left untreated, may progress to end-stage kidney failure (ESKF). Identifying individuals at an increased risk of kidney disease and who might benefit from a therapeutic or preventive intervention is an important challenge. AIM: To evaluate the performance of the QKidney® scores for predicting 5-year risk of developing moderate-severe kidney disease and ESKF in an independent UK cohort of patients from general practice records. DESIGN AND SETTING: Prospective cohort study to evaluate the performance of two risk scores for kidney disease in 364 practices from the UK, contributing to The Health Improvement Network (THIN) database. METHOD: Data were obtained from 1.6 million patients registered with a general practice surgery between 1 January 2002 and 1 July 2008, aged 35-74 years, with 43,186 incident cases of moderate-severe kidney disease and 2663 incident cases of ESKF. This is the first recorded evidence of moderate-severe chronic kidney and ESKF as recorded in general practice records. RESULTS: The results from this independent and external validation of QKidney scores indicate that both scores showed good performance data for both moderate-severe kidney disease and ESKF, on a large cohort of general practice patients. Discrimination and calibration statistics were better for models including serum creatinine; however, there were considerable amounts of missing data for serum creatinine. QKidney scores both with and without serum creatinine were well calibrated. CONCLUSION: QKidney scores have been shown to be useful tools to predict the 5-year risk of moderate-severe kidney disease and ESKF in the UK.
Authors: Nynke Halbesma; Desiree F Jansen; Martijn W Heymans; Ronald P Stolk; Paul E de Jong; Ronald T Gansevoort Journal: Clin J Am Soc Nephrol Date: 2011-07 Impact factor: 8.237
Authors: Abhijit V Kshirsagar; Heejung Bang; Andrew S Bomback; Suma Vupputuri; David A Shoham; Lisa M Kern; Philip J Klemmer; Madhu Mazumdar; Phyllis A August Journal: Arch Intern Med Date: 2008-12-08
Authors: Pankti A Gheewala; Syed Tabish R Zaidi; Matthew D Jose; Luke Bereznicki; Gregory M Peterson; Ronald L Castelino Journal: J Nephrol Date: 2017-02-08 Impact factor: 3.902
Authors: Jan C van Blijderveen; Sabine M Straus; Robert Zietse; Bruno H Stricker; Miriam C Sturkenboom; Katia M Verhamme Journal: Int Urol Nephrol Date: 2013-09-27 Impact factor: 2.370
Authors: Emily B Schroeder; Stan Xu; Glenn K Goodrich; Gregory A Nichols; Patrick J O'Connor; John F Steiner Journal: J Diabetes Complications Date: 2017-04-11 Impact factor: 2.852
Authors: Emily B Schroeder; Xiuhai Yang; Micah L Thorp; Brent M Arnold; David C Tabano; Amanda F Petrik; David H Smith; Robert W Platt; Eric S Johnson Journal: Clin J Am Soc Nephrol Date: 2016-12-27 Impact factor: 8.237
Authors: Mohammad Tahir; Simon Hassan; Simon de Lusignan; Lazza Shaheen; Tom Chan; Olga Dmitrieva Journal: BMC Nephrol Date: 2014-05-07 Impact factor: 2.388
Authors: Ahmed Bakillah; Fasika Tedla; Isabelle Ayoub; Devon John; Allen J Norin; M Mahmood Hussain; Clinton Brown Journal: Mediators Inflamm Date: 2015-11-15 Impact factor: 4.711